NCT02106507View on ClinicalTrials.gov

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 28, 2021

Study Completion Date

June 28, 2021

Conditions

Prostate Cancer

Interventions

DRUG

apalutamide

apalutamide, 240 mg/day, oral

DRUG

Everolimus

5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York